Skip to main content
Download PDF
  • Study Protocol
  • Open access
  • Published:

The effect of lavender aroma for anxiety disorder: a study protocol for a multicenter, double-masked, randomized, placebo-controlled clinical trial

BMC Complementary Medicine and Therapies volume 23, Article number: 397 (2023) Cite this article

Abstract

Background

Anxiety disorder is the most prevalent psychiatric disorder. Benzodiazepines, which are often used for anxiety in patients with anxiety disorder, have various side effects. Lavender, one of the most commonly used essential oils in aromatherapy, has the potential to reduce benzodiazepine use for anxiety disorders.

Methods

This study is a multicenter, double-masked, randomized, placebo-controlled clinical trial. The study will recruit patients aged 20–59 years old with generalized anxiety disorder and panic disorder among anxiety disorders. The bottle containing the test solution (lavender aroma essential oil or distilled water) will be given to the patients. Patients will carry the bottles with them in their daily life and use the drops on tissue paper when anxious. The primary endpoint is the number of times anxiolytics used in 28 days.

Discussion

If the use of benzodiazepines could be reduced by sniffing lavender aroma, which is inexpensive and safe, it would contribute not only to the risks associated with benzodiazepine use but also to the health care economy and could even be added as a standard treatment.

Trial registration

University hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), ID: UMIN000034422 Registered 17 January 2019.

Peer Review reports

Background

Anxiety disorder is an extremely common mental disorder [1], and its frequency has increased over the last decade [2]. A meta-analysis conducted by Lijster et al. showed that 21.3 years is the average age at the onset of anxiety disorders [3]. In the European Study of the Epidemiology of Mental Disorders, an international epidemiological study conducted in Europe (Belgium, France, Germany, Italy, the Netherlands, and Spain) among people aged 18 years and older, the lifetime prevalence of anxiety disorders was 13.6% [4]. The World Mental Health Japan Survey, conducted among Japanese residents aged 20–75, reported a 10.8% lifetime prevalence of anxiety disorders [5]. Anxiety disorders have been found to contribute to increased rates of absenteeism in both work and educational settings, resulting in a greater financial burden when compared to other mental diseases [6]. According to the fifth version of Diagnostic and Statistical Manual of Mental Disorders (DSM)-5, major anxiety disorders that affect adults include generalized anxiety disorder (GAD), panic disorder (PD), social anxiety disorder (SAD), agoraphobia, and specific phobia [7].

The most common treatment for anxiety disorders is a combination of pharmacotherapies, including the use of benzodiazepines [8], serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors [9], and psychotherapy (cognitive behavioral therapy) [10, 11]. Usually, patients with anxiety disorders use benzodiazepines for transient anxiety symptoms such as panic attacks. However, their prolonged use may have adverse health effects despite their short-term benefits. These factors encompass the potential for dependence and adverse outcomes, such as cognitive decline [12, 13].

Aromatherapy is one of the most extensively used supplementary therapies [14]. It is based on the therapeutic application of essential oils produced from aromatic herbs that can be ingested, applied topically to the skin, or inhaled [15]. Some essential oils have been known as anxiolytic candidates, namely lavender, also known as Lavandula angustifolia Mill. A randomized placebo-controlled study of 116 volunteers showed reduced stress levels in the group using lavender oil for aromatherapy compared with the placebo group [16]. In adults with GAD, the orally administered anxiolytic effect was comparable to that of benzodiazepines [17] and SSRIs [18], and fewer adverse effects were reported than with synthetic drugs.

The aforementioned research may suggest the possibility of aromatherapy as a treatment for anxiety disorders. However, these do not include studies of inhaling or sniffing essential oil. While inhaling essential oils changes moods in healthy volunteers [19], a study on women undergoing abortions indicates that aromatherapy cannot be substituted for anxiolytics [20]. Therefore, anxiolytic effects of inhaling essential oils still need to be elucidated. Additionally, it should be noted that inhaling and sniffing may exhibit different effects because inhaling essential oil means the oil is gas while sniffing means the oil can be in various forms, such as liquid or solid.

In summary, to the best of our knowledge, the possibility of chronic exposure to sniffed essential oil as an aromatherapy for treating anxiety disorders has never been evaluated. Therefore, the effect of sniffing fragrance in aromatherapy should be elucidated first before delving into which essential oils show an anxiolytic effect.

In this study, starting with lavender as our initial focus, we will investigate the efficacy and safety of sniffing lavender aroma in patients with anxiety disorders, aiming to develop a reliable and safe alternative and complementary treatment.

Design

Study design

This study is a multicenter, double-blind, randomized, and placebo-controlled clinical trial. To compare the effectiveness of treatment with lavender aroma, we will compare two groups of patients: a lavender aroma group and a non-lavender aroma group who were provided with a placebo. Double masking is necessary due to the possibility of changes in medical treatment once the researcher knows the allocation results.

Patients

The study will include patients aged 20–59 with GAD and PD among anxiety disorders diagnosed using the DSM-5. The study dates ranged between September 9, 2018, and March 31, 2024. Posters and other methods will be for study recruitment. We will explain everything using permission from the explanatory paper and consent forms, and we will obtain everyone’s signed consent. Written informed consent will be obtained from all the participants. Moreover, participants can withdraw at anytime after participating in this study.

Inclusion criteria

Patients must satisfy the following requirements:

  1. 1.

    Only female patients aged 20–59 who consented to the study.

  2. 2.

    Patients who were diagnosed with GAD or PD using the DSM-5.

  3. 3.

    Patients who have taken anxiolytics more than seven times within the past month.

  4. 4.

    Patients with no history of aroma use.

Basis for setting inclusion criteria

  1. 1.

    The patient’s age was defined as the age when the patient consented to the study. The effectiveness of the aroma may differ according to sex. To detect efficacy efficiently, the study needed to be limited to a more homogeneous population and was therefore limited to female patients only.

  2. 2.

    Patients with GAD and PD were chosen as they are most frequently encountered in daily practice.

  3. 3.

    We included patients who took anxiolytics because we expected these patients to benefit from the treatment.

  4. 4.

    Patients who had never used aroma-related products were chosen to eliminate the possibility that a history of aroma use influenced this study.

Exclusion criteria

Patients who fell into the following criteria below are excluded from the study.

  1. 1.

    Patients who are diagnosed with significant physical and mental health issues by the physician in charge.

  2. 2.

    Patients who are pregnant, possibly pregnant, within 28 days postpartum, or are breastfeeding.

  3. 3.

    Patients who are diagnosed with any olfactory dysfunction or chronic nasal obstruction.

  4. 4.

    Patients with dilated thoughts of death.

  5. 5.

    Patients using anxiolytics other than benzodiazepines as an abortive medication for anxiety attacks.

  6. 6.

    Any patients deemed ineligible by the principal investigator or sub-investigator for this study were excluded.

Basis for setting exclusion criteria

The above criteria in points 1, 4, and 6 were used to ensure the general safety of the patients.

Point 2 was established because the safety of the patient treatment for pregnant women, fetuses, and newborns was not established.

Points 3 and 5 were established to exclude patients who would be affected by the evaluation of the treatment under study.

Interventions

The study schedule is depicted in Fig. 1. After obtaining the 4-week baseline benzodiazepine medication status and other information, the patients will be assigned to either the aromatherapy or distilled water (placebo) groups. The patient will begin carrying the bottle immediately after the outpatient visit, and in this study, carrying is defined as carrying the bottle at all times in a bag or similar while going out. However, for the time spent at home, the patient is considered to be carrying the bottle because the test solution is always available if the patient experienced anxiety attacks.

Fig. 1
figure 1

Flowchart of the study schedule. GAD = generalized anxiety disorder; PD = panic disorder; STAI = State Trait Anxiety Inventory; SDS = Self-Rating Depression Scale; GHQ60 = General Health Questionnaire 60; PSQI = Pittsburgh Sleep Quality Index

Full size image

Lavender aroma (L. angustifolia ssp. Angustifolia (Pranarom International, Ghislenghien, Belgium) or distilled water is used as the test solution, which is stored in a 10 ml glass bottle with a drop stopper (Pranarom International). The bottle containing the test solution (lavender aroma essential oil or distilled water) will be given to the patient without informing them of the type of test solution. Patients will be asked to carry the bottles with them daily at all times and use the drops on the tissue paper when anxious. The patients will be instructed to maintain a diary in which they will record details on their benzodiazepine medication and aroma usage (Supplementary Fig. 1).

Data management

The study data will be collected and stored in the Research Electronic Data Capture system (REDCap), a web-based, secure, Health Insurance Portability and Accountability Act-compliant research management platform [21, 22], which is also an electronic data capture system for electronically gathering clinical data in clinical research. This system provides comprehensive support for various research procedures, encompassing patient scheduling, patient randomization, data entry and management, data safety monitoring, and adverse event reporting. One of the main advantages of REDCap is that it requires a thorough audit trial. The individual providing the input is also immediately alerted if any field is blank or values outside the acceptable range are entered. Backup paper copies were given when internet connectivity was lost, and these copies were then entered into REDCap.

The study database will not contain any personal identifiers, such as names or other information that might potentially lead to the direct identification of a patient by a third party; instead, the enrolled patients’ data were accessed and queried using the REDCap software. To prevent unauthorized access, the datasets saved on computers are password-protected and encrypted. Patients will be identified by numbers or symbols, and the relationship between these and details that may be used to quickly identify a person (such as name or address) to a third party will not be maintained during data collection. It is necessary to maintain a record of the correspondence between information that is clearly identifiable to a third party (such as name and address) in a locked cabinet (personal information manager: HA).

Primary endpoint

The primary outcome measure is the number of times anxiolytics were used within 28 days.

Secondary endpoint

  1. 1.

    Total amount of anxiolytic used (diazepam equivalent)

  2. 2.

    Change in State Trait Anxiety Inventory (STAI) total score from baseline at 28 days.

    1. 2.1.

      Change from baseline in state anxiety total score at 28 days.

    2. 2.2.

      Change from baseline in trait anxiety total score at 28 days.

    The STAI is a 40-item self-report scale that assesses the presence and intensity of anxiety symptoms as well as the generalized tendency to be anxious [23]. By asking patients how they feel “right now”, the State Anxiety Scale assessed their present level of anxiety, including their subjective emotions of tension, uneasiness, concern, and activation of their autonomic nervous system. There are 20 elements in total, with values ranging from 0–2. The Trait Anxiety Scale measures characteristics of anxiety propensity that are generally constant, such as overall tranquility, assurance, and security [24]. There were 20 items in total, with values ranging from 0–2. Higher ratings indicate severe anxiety.

  3. 3.

    Change in Self-Rating Depression Scale (SDS) total score from baseline at 28 days.

    The SDS, which includes 20 items on sadness, crying easily, and sleep disorders, is used to assess patients’ depression and changes in therapeutic processes [25]. The scoring system adopts a 4-level scoring system, among which 10 items are positive scoring and the other 10 items are negative scoring. A score < 53 indicates normal, a score 53–72 indicates depression, and a score > 72 indicates major depression. The severity of the depression increases with score.

  4. 4.

    Change in the General Health Questionnaire 60 (GHQ60) total score from baseline at 28 days.

    The GHQ60 is a 60-item self-rating scale with a range of 0–60 that assesses physical and mental suffering and the likelihood of developing psychiatric illnesses. A high risk of neurosis is indicated by a score of 17 or above [26].

  5. 5.

    Change in the Pittsburgh Sleep Quality Index (PSQI) total score from baseline at 28 days.

    A self-rated questionnaire called the PSQI rates a month’s worth of sleep disruption and quality. The seven “component” scores, namely subjective sleep quality, sleep latency, sleep length, habitual sleep efficiency, sleep disturbances, utilization of sleeping drugs, and daytime dysfunction, are derived from the analysis of the 19 individual items. The cumulative score is derived from the summation of the points attributed to each of the seven constituent components. An overall score of 5 or above is indicative of poor sleep quality [27].

  6. 6.

    Number of anxiety attacks.

Sample size calculation

Among the patients treated by the principal investigators and research assistants at the facilities where this study was conducted, those with anxiety disorders suitable for the study generally used anxiolytic medications 30 times/month. We expected the use of lavender aroma would decrease this frequency to about 10 times/month and assumed that the difference in the mean frequency between the distilled water group and the lavender aroma group would be -10 ± 7.5 times/month. If a two-sample t-test is conducted with a two-sided significance level of 5% and power of 80%, 10 patients per group are required. The total sample size is 30 (15 per group), considering that discontinuation or dropout occurs approximately 30% of the time.

Randomization

Four weeks after the start date, the patients will be allocated to two groups in a random manner, employing a stratified permuted block approach (stratification factors are the primary illness (GAD or PD)) on REDCap. The results of the assignment will be indicated by a number, and a bottle containing the test solution (lavender aroma essential oil or distilled water) will be provided by the Department of Orthodontics, Kagoshima University Graduate School of Dentistry, where the bottles containing the test solution matching the number will be kept without informing the investigators or patients of the type of test solution.

Statistical analysis

Analysis set

For the next analysis sets, statistical analysis will be done.

  1. 1.

    Full analysis set (FAS)

    All patients will be regarded as FAS, with the exception of those who received care in flagrant violation of ethical standards, those who were not given the test solution, and those whose data for the key outcome were missing.

  2. 2.

    Safety analysis set (SAS)

    The SAS will be referred to as the group of patients to whom the test solution was distributed.

  3. 3.

    Per protocol set (PPS)

    The PPS will be referred to as the group of patients who fall under the FAS but do not match the criteria below.

    1. 3-1.

      Patients who fail to satisfy the predetermined inclusion criteria or contravene the established exclusion criteria for this study

    2. 3-2.

      Notable departures from the established study procedure

    3. 3-3.

      Patients who had not carried a bottle containing the test solution for more than 20 days

Summary between treatment groups

For each FAS, patient backgrounds will be tallied by therapy group. For continuous data, summary statistics will be provided, and for categorical data, frequencies and proportions (%) will be shown.

Primary endpoint

The primary endpoint analysis will be based on the FAS. A sensitivity analysis will be conducted on the PPS to confirm the robustness of the results. This will be analysed using an analysis of covariance model for the change from the baseline to 28 days in the number of times anxiolytic medication is used, with treatment and the baseline value as covariates.

In case of discontinuation, dropout, the number of times anxiolytics per period will be converted to 28 days for the analysis. Missing values will not be imputed.

Secondary endpoints

Secondary endpoints will be analysed in the same way as that for the primary endpoint.

All statistical analyses will be performed with SAS software (version 9.4; SAS Institute, Cary, NC, USA).

Interim analyses

No interim analysis is planned.

Monitoring

To ensure that this study is being carried out properly, the lead investigator will request that the institution perform monitoring. As a usual practice, the monitoring report will be submitted annually.

Adverse events

The incidence of adverse events is minimal, and no discernible health or safety concerns have been reported in relation to the participants included in the clinical research. The safety monitoring group will oversee data monitoring. Throughout the course of the 1-week program, any small or significant occurrences related to the intervention or routine care groups will be observed. The chief investigator will review any negative or unexpected consequences.

Discussion

The objective of this study is to examine the effectiveness and safety of olfactory exposure to essential oil fragrance among individuals diagnosed with anxiety disorders, with the aim of establishing a dependable and secure alternative and adjunctive therapeutic approach for anxiety management in this population. Lavender was taken as a starting point for exploring the use of essential oil fragrances as potential anxiolytic treatments, because a systematic review of aromatherapy on anxiety clearly indicates that it is the major fragrance [28]. Considering this objective, the placebo should meet the following criteria: 1) Be indiscernible from its appearance, i.e., a colorless clear liquid; 2) Having no fragrances. Therefore, our placebo of distilled water is justified. In fact, a systematic review of lavender as a potential anxiolytic supports that using distilled water as a placebo is appropriate [29].

However, there are some limitations to be considered. First, it should be noted that secondary endpoints of STAI, SDS, GHQ60, and PSQI are subjective. Therefore, patients’ objective psychological states or sleep qualities, such as functional magnetic resonance imaging, heart rate variability, or polysomnography might strengthen our findings. Because these were not the primary endpoint, we do not perform further objective assessment. Second, the primary endpoint of the number of times anxiolytics used is not completely objective. Although the possibility may not be high, we should be cautious about the accuracy of patients’ reporting of their anxiolytics use.

Last but not least, limitations of statistical analyses should be seriously discussed. The difference of primary endpoint in the mean frequency of benzodiazepine use between the distilled water group and the lavender aroma group of -10 ± 7.5 times/month was derived from a simple assumption. Therefore, we cannot deny the possibility of manipulating the sample size. Nonetheless, this assumption was based on our clinical experience of patients with mood disorders by the intervention of complementary medicine, such as mindfulness. Another statistical limitation lies in imputation. If missing values tend to appear in one common characteristic of patients, using imputation to handle such patients could reveal significant insights. However, because the sample size was calculated considering dropout rate of 30%, and such analysis can be performed separately, we decided to perform no imputation.

Considering aforementioned limitations, if the use of benzodiazepines could be reduced by sniffing inexpensive and safe essential oils, including lavender, this would contribute not only to the risks associated with benzodiazepine drug use, but also to the health care economy. In addition, since sniffing aromas is simpler than taking medications with drinking water, the use adherence is likely to be higher and it could be added as a standard treatment.

Availability of data and materials

Not applicable.

Abbreviations

AMED:

Japan Agency for Medical Research and Development

FAS:

Full analysis set

GAD:

Generalized anxiety disorder

GHQ60:

General Health Questionnaire 60

PD:

Panic disorder

PPS:

Per protocol set

PSQI:

Pittsburgh Sleep Quality Index

SAD:

Social anxiety disorder

SAS:

Safety analysis set

SSRIs:

Serotonin reuptake inhibitor

STAI:

Stait Trait Anxiety Inventory

REDCap:

Research electronic data capture system

References

  1. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-35.

  2. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.

    Article  Google Scholar 

  3. De Lijster JM, Dierckx B, Utens EM, Verhulst FC, Zieldorff C, Dieleman GC, et al. The age of onset of anxiety disorders: a meta-analysis. Can J Psychiatry Rev Can Psychiatr. 2017;62(4):237.

    Article  Google Scholar 

  4. ESEMeD/MHEDEA 2000 Investigators, Alonso J, Angermeyer M, Bernert S, Bruffaerts R, Brugha T, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109:21–7.

    Article  Google Scholar 

  5. Ishikawa H, Kawakami N, Kessler R, World Mental Health Japan Survey Collaborators. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of World Mental Health Japan Survey. Epidemiol Psychiatr Sci. 2016;25(3):217–29.

    Article  CAS  PubMed  Google Scholar 

  6. Ahola K, Virtanen M, Honkonen T, Isometsä E, Aromaa A, Lönnqvist J. Common mental disorders and subsequent work disability: a population-based Health 2000 Study. J Affect Disord. 2011;134(1–3):365–72.

    Article  PubMed  Google Scholar 

  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington: American Psychiatric Association; 2013.

    Book  Google Scholar 

  8. Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological management of anxiety disorders in the elderly. Curr Treat Options Psychiatry. 2017;4:33–46.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Charlson F, van Ommeren M, Flaxman A, Cornett J, Whiteford H, Saxena S. New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. Lancet. 2019;394(10194):240–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Stewart RE, Chambless DL. Cognitive–behavioral therapy for adult anxiety disorders in clinical practice: a meta-analysis of effectiveness studies. J Consult Clin Psychol. 2009;77(4):595.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis. 2007;195(6):521–31.

    Article  PubMed  Google Scholar 

  12. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18:37–48.

    Article  CAS  PubMed  Google Scholar 

  13. Zetsen SP, Schellekens AF, Paling EP, Kan CC, Kessels RP. Cognitive functioning in long-term benzodiazepine users. Eur Addict Res. 2022;28(5):377–81.

    Article  PubMed  Google Scholar 

  14. Kyle G. Evaluating the effectiveness of aromatherapy in reducing levels of anxiety in palliative care patients: results of a pilot study. Complement Ther Clin Pract. 2006;12(2):148–55.

    Article  PubMed  Google Scholar 

  15. How Essential Oils Work. In Clinical Aromatherapy (Third Edition) Essential Oils in Healthcare. London: Elsevier; 2016.

  16. Ahmad R, Naqvi AA, Al-Bukhaytan HM, Al-Nasser AH, Al-Ebrahim AHB. Evaluation of aromatherapy with lavender oil on academic stress: a randomized placebo controlled clinical trial. Contemp Clin Trials Commun. 2019;14:100346.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17(2):94–9.

    Article  CAS  PubMed  Google Scholar 

  18. Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder–a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859–69.

    Article  CAS  PubMed  Google Scholar 

  19. Moss M, Cook J, Wesnes K, Duckett P. Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. Int J Neurosci. 2003;113(1):15–38.

    Article  PubMed  Google Scholar 

  20. Wiebe E. A randomized trial of aromatherapy to reduce anxiety before abortion. Eff Clin Pract ECP. 2000;3(4):166–9.

    CAS  PubMed  Google Scholar 

  21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.

    Article  PubMed  Google Scholar 

  22. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Spielberger CD. Manual for the State-Trait Anxiety Inventory (self-evaluation questionnaire). No Title. 1970.

  24. Julian LJ. Measures of anxiety. Arthritis Care Res. 2011;63(0 11):467–72.

    Google Scholar 

  25. Zung WW, Gianturco JA. Personality dimension and the Self-rating Depression Scale. J Clin Psychol. 1971;27(2):247–8.

    Article  CAS  PubMed  Google Scholar 

  26. Goldberg P. The detection of psychiatric illness by questionnaire. Maudsley monograph No. 21. London: Oxford University Press; 1972.

  27. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.

    Article  CAS  PubMed  Google Scholar 

  28. Gong M, Dong H, Tang Y, Huang W, Lu F. Effects of aromatherapy on anxiety: a meta-analysis of randomized controlled trials. J Affect Disord. 2020;1(274):1028–40.

    Article  Google Scholar 

  29. Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F. Effects of lavender on anxiety: a systematic review and meta-analysis. Phytomedicine. 2019;1(65):153099.

    Article  Google Scholar 

Download references

Acknowledgements

We express our gratitude to the Japan Agency for Medical Research and Development (AMED) for their help in facilitating this study.

Funding

The present study received financial assistance from AMED under Grant Number JP18lk0310047.

Author information

Author notes

  1. Ryusei Nishi and Kenichiro Sagiyama contributed equally to this work.

Authors and Affiliations

  1. Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    Haruka Amitani, Ryusei Nishi, Kenichiro Sagiyama, Takamasa Fukumoto & Akihiro Asakawa

  2. Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan

    Kouta Funakoshi, Naomi Takayanagi, Hiroko Watanabe, Masayuki Hirose & Koshiro Tagawa

  3. Center for Clinical Research and Innovation, Osaka City University Hospital, Osaka, Japan

    Keiko Ota

  4. Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan

    Yoichi M. Ito

Authors
  1. Haruka Amitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryusei Nishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenichiro Sagiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takamasa Fukumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kouta Funakoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naomi Takayanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroko Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masayuki Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koshiro Tagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keiko Ota
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoichi M. Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Akihiro Asakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AA was accountable for the initial development and design of the procedure. HA, TF and KF made significant contributions to the initial literature review, which served as the foundation for establishing the rationale and context of the study. KO built the REDCap system for this study. YI, NT, KF, HW, MH, KT, KO and NN provided guidance on the selection of appropriate methodology design and statistical analysis approaches. HA wrote the original draft of the manuscript. RN and KS made significant contributions to revising the draft. The final paper was collaboratively contributed to and approved by all writers.

Corresponding author

Correspondence to Akihiro Asakawa.

Ethics declarations

Ethics approval and consent to participate

The present work has received approval from the ethical review board of Kagoshima University (No: 180131).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplementary Figure 1.

Diary of use of test solution and anxiolytics.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amitani, H., Nishi, R., Sagiyama, K. et al. The effect of lavender aroma for anxiety disorder: a study protocol for a multicenter, double-masked, randomized, placebo-controlled clinical trial. BMC Complement Med Ther 23, 397 (2023). https://doi.org/10.1186/s12906-023-04231-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-023-04231-1

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us